0001104659-26-060382
SEC filingCapricor reported significantly wider operating and net losses in Q1 FY2026 versus Q1 FY2025, with free cash flow declining to -$34.4M — reflecting intensified pre-commercial investment as the company advances toward the anticipated August 2026 FDA decision on Deramiocel.
The Company’s financial results for Q1 FY2026 reflect a deliberate acceleration of pre-commercial investment, as explicitly described in management’s discussion: 'The decrease in cash, cash equivalents and marketable securities from December 31, 2025 to March 31, 2026 is primarily due to our continuing efforts in preparing the Company for potential commercialization.' This strategic posture underpins all major financial movements this quarter.
Despite the elevated cash burn, management reaffirms its liquidity assessment: 'We believe that our current cash, cash equivalents, and marketable securities are sufficient to fund our operating capital requirements for at least the next twelve months from the issuance date of these condensed consolidated financial statements.' This statement anchors investor understanding of runway — a critical consideration given the Company’s reliance on future funding, as underscored by the outlook context: 'As we seek to develop and commercialize Deramiocel or any other product candidates... we anticipate that our expenses will increase significantly and that we will need additional funding to support our continuing operations.'